LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics



Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company developing a novel generation of immune modulators. The round of €20m was funded by LSP, alongside Boehringer Ingelheim Venture Fund (BIVF) and Kurma Partners and Gimv.
 
The funding will support the development of two assets in immuno-oncology. Immuno-oncology has unfolded its potential over recent years, with products increasing the human body natural defences, namely the immune defence, to recognize and kill tumors.  The assets developed by Imcheck Therapeutics represent first-in-class drugs, as the immune modulation is mediated through gamma-delta T cells, a subsets of T cells recently identified as playing a major part in tumor rejection, thus a step further than checkpoint inhibitors already commercialized or in development. Imcheck will also develop these assets in treating auto-immune disorders and infectious diseases. The funding is further aimed at advancing several discovery programs that focus on undisclosed targets, ones that play a defined immune-modulating role in innate and adaptive immunity.

A link to the company's press release can be found at here
 
About Imcheck Therapuetics 
Imcheck Therapeutics is a privately held French biotech company pioneering the next generation of immune checkpoint modulators. It holds a highly diverse portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity.
As a spin-off from Marseille’s Institut Paoli-Calmettes, one of Europe's leading cancer centers, Imcheck was founded in 2015 around Prof. Daniel Olive, a pioneer in innate immunity and co signaling molecules and head of the immune monitoring program for early-stage clinical trials in oncology.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders in the global life-science industry. With over 1 billion USD of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact:
Vincent Brichard, Venture Partner LSP
+31 (0) 20 6645500
ioevpuneq@yfcip.pbz
 
Joachim Rothe, Managing Partner LSP
+49 (0) 89 330 666-0
webgur@yfcip.pbz
 
 
 
 
« back to overview

LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics



Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company developing a novel generation of immune modulators. The round of €20m was funded by LSP, alongside Boehringer Ingelheim Venture Fund (BIVF) and Kurma Partners and Gimv.
 
The funding will support the development of two assets in immuno-oncology. Immuno-oncology has unfolded its potential over recent years, with products increasing the human body natural defences, namely the immune defence, to recognize and kill tumors.  The assets developed by Imcheck Therapeutics represent first-in-class drugs, as the immune modulation is mediated through gamma-delta T cells, a subsets of T cells recently identified as playing a major part in tumor rejection, thus a step further than checkpoint inhibitors already commercialized or in development. Imcheck will also develop these assets in treating auto-immune disorders and infectious diseases. The funding is further aimed at advancing several discovery programs that focus on undisclosed targets, ones that play a defined immune-modulating role in innate and adaptive immunity.

A link to the company's press release can be found at here
 
About Imcheck Therapuetics 
Imcheck Therapeutics is a privately held French biotech company pioneering the next generation of immune checkpoint modulators. It holds a highly diverse portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity.
As a spin-off from Marseille’s Institut Paoli-Calmettes, one of Europe's leading cancer centers, Imcheck was founded in 2015 around Prof. Daniel Olive, a pioneer in innate immunity and co signaling molecules and head of the immune monitoring program for early-stage clinical trials in oncology.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders in the global life-science industry. With over 1 billion USD of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact:
Vincent Brichard, Venture Partner LSP
+31 (0) 20 6645500
ioevpuneq@yfcip.pbz
 
Joachim Rothe, Managing Partner LSP
+49 (0) 89 330 666-0
webgur@yfcip.pbz
 
 
 
 
« back to overview